CL2023003455A1 - Engineered polypeptides - Google Patents

Engineered polypeptides

Info

Publication number
CL2023003455A1
CL2023003455A1 CL2023003455A CL2023003455A CL2023003455A1 CL 2023003455 A1 CL2023003455 A1 CL 2023003455A1 CL 2023003455 A CL2023003455 A CL 2023003455A CL 2023003455 A CL2023003455 A CL 2023003455A CL 2023003455 A1 CL2023003455 A1 CL 2023003455A1
Authority
CL
Chile
Prior art keywords
polypeptides
engineered polypeptides
variants
polypeptide
igg
Prior art date
Application number
CL2023003455A
Other languages
English (en)
Spanish (es)
Inventor
Snell Gyorgy
Corti Davide
Czudnochowski Nadine
Telenti Amalio
Bartha Istvan
Alexander Schmid Michael
Original Assignee
Vir Biotechnology Inc
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc, Humabs Biomed Sa filed Critical Vir Biotechnology Inc
Publication of CL2023003455A1 publication Critical patent/CL2023003455A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2023003455A 2021-05-24 2023-11-21 Engineered polypeptides CL2023003455A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192549P 2021-05-24 2021-05-24
US202163265032P 2021-12-06 2021-12-06
US202263266453P 2022-01-05 2022-01-05

Publications (1)

Publication Number Publication Date
CL2023003455A1 true CL2023003455A1 (es) 2024-07-19

Family

ID=82156443

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003455A CL2023003455A1 (es) 2021-05-24 2023-11-21 Engineered polypeptides

Country Status (13)

Country Link
US (1) US20250296986A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347642A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024521131A (cg-RX-API-DMAC7.html)
KR (1) KR20240035758A (cg-RX-API-DMAC7.html)
AU (1) AU2022280767A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024494A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218489A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003455A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023017754A2 (cg-RX-API-DMAC7.html)
IL (1) IL308509A (cg-RX-API-DMAC7.html)
MX (1) MX2023013859A (cg-RX-API-DMAC7.html)
TW (1) TW202306978A (cg-RX-API-DMAC7.html)
WO (1) WO2022251119A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CA3183373A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
JP2025526405A (ja) 2022-07-27 2025-08-13 ヒューマブス・バイオメッド・ソシエテ・アノニム Rsv及びmpvパラミクソウイルスに対する広域中和抗体
WO2024182781A1 (en) 2023-03-02 2024-09-06 Vir Biotechnology, Inc. Coronavirus compositions and uses thereof
TW202446788A (zh) 2023-04-10 2024-12-01 美商維爾生物科技公司 結合多種薩貝冠狀病毒之抗體
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
EP4743488A1 (en) 2023-07-13 2026-05-20 VIR Biotechnology, Inc. Antibodies widely neutralizing against paramyxoviruses RSV and MPV

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2005028515A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
WO2010033279A2 (en) * 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
CN103261222B (zh) 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
US9663581B2 (en) 2012-04-25 2017-05-30 Momenta Pharmaceuticals, Inc. Modified glycoproteins
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
US20160257761A1 (en) * 2015-03-06 2016-09-08 Macrogenics, Inc. HER2/neu-Specific Antibodies and Methods of Using Same
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
US20200157192A1 (en) * 2017-05-10 2020-05-21 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
JP7351845B2 (ja) * 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections

Also Published As

Publication number Publication date
WO2022251119A2 (en) 2022-12-01
AU2022280767A1 (en) 2024-01-18
EP4347642A2 (en) 2024-04-10
WO2022251119A9 (en) 2023-10-05
MX2023013859A (es) 2024-02-15
IL308509A (en) 2024-01-01
TW202306978A (zh) 2023-02-16
CO2023017754A2 (es) 2024-05-10
CA3218489A1 (en) 2022-12-01
WO2022251119A3 (en) 2023-01-12
US20250296986A1 (en) 2025-09-25
JP2024521131A (ja) 2024-05-28
BR112023024494A2 (pt) 2024-02-06
KR20240035758A (ko) 2024-03-18

Similar Documents

Publication Publication Date Title
CO2023017754A2 (es) Polipéptidos modificados
CU20200090A7 (es) Anticuerpos frente a entpd2 y terapias de combinación
CL2020000039A1 (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes. (divisional solicitud 201700647)
MX2022006078A (es) Terapias de combinacion para el tratamiento del cancer.
SA521421825B1 (ar) (glp1) البروتينات الاندماجية المتمثلة في الببتيد 1 الشبيه بالجلوكاجون (gdf15) وعامل تمايز النمو 15 واستخدامه
CO2018005436A2 (es) Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica
MX2016008782A (es) Variantes de region fc con union mejorada de la proteina a.
DOP2017000047A (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
UY37576A (es) Anticuerpos dirigidos a hueso
CL2015002720A1 (es) Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc.
ECSP22049014A (es) Variantes de progranulina
WO2006036550A3 (en) Listeria-based and llo-based vaccines
MX2024004294A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
CL2008000104A1 (es) Proteina de fusion que comprende un antigeno asociado a tumor (prame) o un fragmento inmunogenico de el y un derivado de proteina d; secuencia nucleotidica que codifica dicha proteina; vector y celula huesped que comprenden la proteina; vacuna que co
BR112023017749A2 (pt) Composições incluindo adjuvantes sbi e métodos de uso das mesmas
PE20230381A1 (es) Proteina de union a rgma
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
MX2021015763A (es) Polipeptidos.
GEAP202515689A (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
MX2020010740A (es) Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso.
EP3784692C0 (en) CYCLIC TYROSINE-TYROSINE PEPTIDE CONJUGATES COUPLED TO A GLUCAGON-RELATED PEPTIDE 1 (GLP-1) FUSION PEPTIDE AND USES THEREOF
CO2024001388A2 (es) Anticuerpos y fragmentos de unión al antígeno anti-glicoproteína de la espícula de sars-cov-2
AR118443A1 (es) Proteínas de fusión, bacterias recombinantes y fragmentos de exosporas para control de plagas y salud de las plantas